Iso-Insulin ELISA

Kit Calculator

Estimate required kits based on your number of samples.

Samples

Article no.

Sample setup

Add the number of samples you plan to run. Please ensure that each sample has sufficient volume to meet the kit’s per-well requirement.

Controls

Add a corresponding Mercodia control kit. Note: If controls are selected, more than one control kit may be needed depending on the number of assay kits used and the time between runs

The results show the estimated number of assay kits required based on your input and the assay’s DfU. Actual kit usage may vary depending on workflow and run frequency.

Minimal Number of Kits Required:

Iso-Insulin ELISA

(10-1128-01)

Kit format: 1 x 96 wells

Measurement range: 3 - 100 mU/L (0.13 - 4.35 µg/L)

Measures total insulin

Cross-reactivity with most insulin analogs

Calibrated against 1st International Reference Preparation 66/304 for human insulin.

CE/IVD labeled on selected markets

Serum controls available: 10-1134-01 (US only) or 10-1164-01

TALK TO A PERSON

Description

Mercodia Iso-Insulin ELISA provides a method for the quantitative determination of human insulin in serum or plasma.

A high quality immunoassay for the quantification of insulin; both endogenous and exogenous. The assay measures common, as well as non-commercially available, insulin analogues and comes with full cross-reactivity data.

Mercodia Diabetes Antigen Control (10-1134-01 (US only) or 10-1164-01) is designed to be used as a two-level control for human insulin.

Test characteristics

Species

Human

Samples

Serum, plasma

Sample volume

25 µL

Assay range

3 - 100 mU/L (0.13 - 4.35 µg/L)

Detection limit

≤ 2 mU/L (0.086 µg/L)

Incubation

1 h + 15 min

Detection method

Absorbance

specificity

The following cross-reactions have been tested:

Insulin

100 %

C-peptide

<0.1 %

Proinsulin

54 %

Proinsulin des (31-32)

58 %

Proinsulin split (32-33)

56 %

Proinsulin des (64-65)

66 %

Proinsulin split (65-66)

78 %

Insulin lispro

112 %

Insulin aspart

100 %

Insulin detemir

28 %

Insulin glargine

58 %

Insulin glulisine

123 %

IGF-I

< 0.02 %

IGF-II

< 0.02 %

Rat insulin

71 %

Mouse insulin

49 %

Porcine insulin

76 %

Ovine insulin

131 %

Bovine insulin

58 %

directions for use Certificate of Analysis

directions for use

LOT. NO.	DOCUMENT
36821	DfU - 10-1128-01 v 17.0
36559	DfU - 10-1128-01 v 17.0
36201	DfU - 10-1128-01 v. 17.0
35079	DfU - 10-1128-01 v. 17.0
35703	DfU - 10-1128-01 v. 17.0

Certificate of Analysis

LOT. NO.	DOCUMENT
36821	CoA - 10-1128-01
36559	CoA - 10-1128-01
36201	CoA - 10-1128-01
35079	CoA - 10-1128-01
35703	CoA - 10-1128-01

For other languages and previous versions: Technical Library

SAFETY DATA SHEET

references

Fink, H., Herbert, C., & Gilor, C. (2018). Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. Domestic Animal Endocrinology, 64, 17–30. Read more >

Regittnig, W. et al. (2019). Insulin Bolus Administration in Insulin Pump Therapy: Effect of Bolus Delivery Speed on Insulin Absorption from Subcutaneous Tissue. Diabetes Technology & Therapeutics, 21(1), 44–50. Read more >

Wang, J. et al. (2019). Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs. Science Advances, 5(7), 4357–4367. Read more >